Rituximab versus tocilizumab in anti-TNF inadequate responder patients with rheumatoid arthritis (R4RA): 16-week outcomes of a stratified, biopsy-driven, multicentre, open-label, phase 4 randomised controlled trial.

ABSTRACT:

SUBMITTER: Humby F 

PROVIDER: S-EPMC7829614 | biostudies-literature | 2021 Jan

REPOSITORIES: biostudies-literature